Ublituximab

Phase 3

TG Therapeutics, Inc. (TGTX)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Q4 '26

TGTXPhase 3$8.6B

Ublituximab Phase 3 Est. Readout

Ublituximab• Non-Hodgkins Lymphoma360

Q4 2026~QConfirmedSTALE

CT.gov

00%

Competitive Landscape

1 competitor in Non-Hodgkins Lymphoma

View Full Landscape

Drug Information

Target Indication

Non-Hodgkins Lymphoma

Clinical Trial

NCT01647971

Last updated: 12/29/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA5/31/2023

Briumvi

Briumvi is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

TGTX

TG Therapeutics, Inc.

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

TeriflunomidePhase 3

Relapsing Multiple Sclerosis (RMS)

UmbralisibPhase 2

Marginal Zone Lymphoma

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts